NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-132-2016-2-US-02 USE OF HETERODIMERIC IL-15 IN ADOPTIVE CELL TRANSFER US National Stage 16/091,967 Pending
NIDCD E-043-2016-0-EP-04 MICRORNAS AND METHODS OF THEIR USE EP National Stage 17712348.6 Pending
NIAID E-118-2016-0-EP-08 Live Attenuated Zika Virus Vaccine EP National Stage 17714066.2 Abandoned
NIDCD E-043-2016-0-EP-01 MICRORNAS AND METHODS OF THEIR USE EP DIV
NIMH E-206-2017-0-PCT-02 SYSTEMS AND METHODS FOR PROBING IN-VIVO METABOLITE RELAXATION BY LINEAR QUANTIFICATION OF SPATIALLY MODULATED MAGNETIZATION PCT PCT PCT/US2018/054340 Expired
NIAID E-052-2017-4-HK-87 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection HK DIV 42021042265.5 Pending
NIAID E-128-2016-0-US-05 MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES US National Stage 16/091,005 11041170 Issued PDF
NIDCD E-043-2016-0-IN-05 MICRORNAS AND METHODS OF THEIR USE IN National Stage 201817037296 Pending
NCI E-266-2011-0-JP-33 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage JP DIV 2018-187094 Issued
NICHD E-552-2013-0-US-24 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE US CON 16/148,435 1106-01-10 Issued PDF
NIAID E-064-2016-1-US-07 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE US National Stage 16/089,993 11174292 Issued PDF
NIAID E-288-2016-0-US-03 Biomarkers And Vaccine Candidates For Filarial Parasites US National Stage 16/090,013 Abandoned
NCI E-266-2011-0-US-32 T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE US DIV 16/144,226 11306131 Issued PDF
NHLBI E-196-2017-0-PCT-02 POLYDOPAMINE-ENCAPSULATED NANODIAMONDS AND METHODS PCT PCT PCT/US2018/053010 Expired
NCI E-190-2014-0-US-15 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS US CON 16/143,147 10588984 Issued PDF
NIAID E-233-2017-0-PCT-02 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES PCT PCT PCT/US2018/052968 Expired
NIAID E-233-2017-0-EP-04 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES EP National Stage 18786583.7 Pending
NIAID E-233-2017-0-CA-03 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES CA National Stage 3074914 Pending
NCATS E-116-2016-0-US-08 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE US National Stage 16/088,371 10919842 Issued PDF
NCATS E-036-2016-0-US-08 METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS US National Stage 16/088,294 Abandoned
NCI E-182-2017-0-PCT-02 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PCT PCT PCT/US2018/052432 Expired
NCI E-182-2017-0-CN-05 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION CN National Stage 201880076862.9 Pending
NCI E-182-2017-0-CA-04 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION CA National Stage 3077595 Pending
NCI E-182-2017-0-AU-03 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION AU National Stage 2018345400 Pending
NCI E-182-2017-0-SG-10 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION SG National Stage 11202003112Q Abandoned
NCI E-182-2017-0-KR-09 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION KR National Stage 2020-7012314 Pending
NCATS E-036-2016-0-JP-07 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders JP National Stage 2018-550327 Pending
NCI E-181-2017-0-TW-05 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS TW ORD 107133221 Issued
NCI E-181-2017-0-AR-03 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS AR ORD P180102695 Pending
NCI E-181-2017-0-JP-16 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS JP National Stage 2020-516422 Issued
NCI E-181-2017-0-US-06 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US ORD 16/135,231 11306132 Issued PDF
NCI E-133-2017-0-PCT-02 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS PCT PCT PCT/US2018/051625 Expired
NCI E-181-2017-0-CN-10 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CN National Stage 201880060535.4 Pending
NCI E-181-2017-0-EP-13 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS EP National Stage 18792591.2 Pending
NCI E-181-2017-0-PCT-02 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS PCT PCT PCT/US2018/051641 Expired
NCI E-181-2017-0-IL-14 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS IL National Stage 273254 Pending
NCI E-181-2017-0-IN-15 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS IN National Stage 202047011647 Pending
NCI E-181-2017-0-CR-11 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CR National Stage 2020-0150 Pending
NCI E-181-2017-0-CA-09 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CA National Stage 3076339 Pending
NCI E-181-2017-0-BR-08 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS BR National Stage BR112020005469-0 Pending
NCI E-181-2017-0-AU-07 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS AU National Stage 2018335274 Pending
NCI E-181-2017-0-NZ-19 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS NZ National Stage 762831 Pending
NCI E-181-2017-0-MX-18 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS MX National Stage MX/a/2020/003117 Pending
NCI E-181-2017-0-SG-20 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS SG National Stage 11202002425P Pending
NCI E-181-2017-0-KR-17 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS KR National Stage 2020-7011112 Pending
NCI E-231-2017-0-PCT-02 IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN PCT PCT PCT/US2018/051418 Expired
NCI E-237-2017-2-EA-07 T CELL RECEPTORS RECOGNIZING MUTATED P53 EA National Stage 202090757 Issued
NCI E-237-2017-1-JP-08 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION JP National Stage 2020-517553 Issued
NCI E-237-2017-2-JP-11 T CELL RECEPTORS RECOGNIZING MUTATED P53 JP National Stage 2020-517556 Issued
NCI E-130-2016-0-US-04 ANTI-pY1235-MET IMMUNOLOGICAL BINDING REAGENT US National Stage 16/085,999 1134-02-19 Issued PDF